Erdosteine

證據等級: L5

預測適應症: 10 個

Erdosteine: From Respiratory Disease (COPD / Chronic Bronchitis) to Marcothrombocytopenia with Mitral Valve Insufficiency

One-Sentence Summary

Erdosteine is a thiol-containing mucolytic and antioxidant agent used for respiratory conditions including COPD and chronic bronchitis, with demonstrated efficacy in reducing acute exacerbation frequency (RESTORE RCT, PMID: 26560176). The TxGNN model predicts it may be effective for Marcothrombocytopenia with Mitral Valve Insufficiency, however, no clinical trials or published literature currently support this direction — this prediction appears to be a knowledge graph structural extrapolation artifact rather than a mechanistically driven finding.

Quick Overview

Item	Content
Original Indication	Respiratory diseases (mucolytic agent; COPD, chronic bronchitis)
Predicted New Indication	Marcothrombocytopenia with Mitral Valve Insufficiency
TxGNN Prediction Score	84.75%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Erdosteine is a thiol-containing mucolytic prodrug that undergoes hepatic metabolism to produce active metabolites (Met-1, Met-2) bearing free sulfhydryl (-SH) groups. These metabolites reduce mucus viscosity by cleaving disulfide bonds in mucus glycoproteins, and additionally exert antioxidant and anti-adhesion effects on respiratory epithelium. Its efficacy and safety in COPD are well-documented in the large-scale RESTORE RCT (PMID: 26560176), providing a solid respiratory safety profile.

The mechanistic leap to marcothrombocytopenia with mitral valve insufficiency is, however, extremely tenuous. Thiol-class compounds such as N-acetylcysteine (NAC) have shown mild antiplatelet aggregation effects in some studies, which may account for Erdosteine's proximity in the TxGNN knowledge graph to platelet-related disease nodes. However, Erdosteine itself has no published platelet-related mechanism data, and the combined syndrome — simultaneously involving thrombocytopenia and cardiac valvular pathology — introduces a heart valve component for which there is no conceivable thiol-drug pathway.

This prediction most likely reflects graph topology rather than pharmacological signal: Erdosteine's thiol-class annotations place it near NAC nodes that carry platelet-related edges in the knowledge graph. Notably, among all 10 predicted indications in this pack, RSV infectious disease (rank 9, score 74.95%) is the most mechanistically aligned with Erdosteine's established respiratory and antioxidant properties, and represents the only candidate worth advancing to S1 safety evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Erdosteine is currently not registered with the Health Sciences Authority (HSA) of Singapore. No Singapore marketing authorizations are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 TxGNN-predicted indications for Erdosteine are at evidence level L5 (model prediction only, with zero supporting clinical trials or publications), and the top-ranked prediction carries essentially no mechanistic connection to Erdosteine's established pharmacology. Singapore regulatory standing is unestablished, with 0 HSA registrations on record.

To proceed, the following is needed:

Obtain Erdosteine's full prescribing information (SmPC / package insert) to resolve the blocking safety data gap — without this, S1 safety evaluation cannot commence
Prioritise RSV infectious disease (rank 9, TxGNN score 74.95%) as the most mechanistically coherent repurposing candidate, and commission a targeted literature review covering Erdosteine + RSV (mucolysis in bronchiolitis, antioxidant attenuation of RSV-induced epithelial oxidative stress)
Consider a secondary mechanistic hypothesis screen for the fibromatosis cluster (Ledderhose disease rank 7, penile fibromatosis rank 8) via thiol-NF-κB / TGF-β antifibrotic pathway analogies drawn from NAC literature before investing in wet-lab work
Re-run TxGNN evidence collection with expanded PubMed queries (e.g., "erdosteine AND respiratory syncytial virus", "erdosteine AND fibrosis") to verify that zero-hit status is not a query-specificity artefact
Assess HSA registration pathway requirements if a viable indication is confirmed downstream
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.